Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:AMBI

AMBI (AMBI) Stock Price, News & Analysis

AMBI logo

About AMBI Stock (NASDAQ:AMBI)

Advanced Chart

Key Stats

Today's Range
$4.82
$4.82
50-Day Range
N/A
52-Week Range
N/A
Volume
742 shs
Average Volume
10,428 shs
Market Capitalization
$267.17 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Ambit Biosciences Corporation is a biopharmaceutical company. The Company focused on the discovery, development and commercialization of drugs to treat unmet medical needs in oncology, autoimmune and inflammatory diseases by inhibiting kinases that are important drivers for those diseases. The Company's lead drug candidate, quizartinib, is in Phase IIb clinical development in patients with relapsed/refractory acute myeloid leukemia (AML). The Company's second drug candidate in clinical development, AC410, is a potent, selective, orally-administered, small molecule inhibitor of Janus kinase 2 (JAK2) that has potential utility for the treatment of autoimmune and inflammatory diseases. The Company's third program consists of two selective small molecule compounds, AC708 and AC855, which inhibit the colony-stimulating factor-1 receptor (CSF1R), a receptor tyrosine kinase.

Receive AMBI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AMBI and its competitors with MarketBeat's FREE daily newsletter.

AMBI Stock News Headlines

Please take this warning seriously...
I’m here to issue a stark warning to you about an unexpected $2 trillion shock that could impact every trader in the country – in the next 30 days. In fact, I believe it could begin as soon as January 29th… Meaning you don’t have much time to prepare.
Ambipar Emergency Response Secures Financial Approval at 2024 AGM
See More Headlines

AMBI Stock Analysis - Frequently Asked Questions

AMBI (NASDAQ:AMBI) announced its earnings results on Tuesday, May, 6th. The biopharmaceutical company reported ($0.50) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.47) by $0.03. The biopharmaceutical company earned $0.03 million during the quarter, compared to analyst estimates of $3.50 million.

Based on aggregate information from My MarketBeat watchlists, some other companies that AMBI investors own include Alexion Pharmaceuticals (ALXN), Amarin (AMRN), Bristol-Myers Squibb (BMY), Broadcom (BRCM), Cytokinetics (CYTK), Delta Air Lines (DAL) and Fortress Biotech (FBIO).

Company Calendar

Last Earnings
5/06/2014
Today
1/21/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Industry
Sanitary services
Sub-Industry
N/A
Current Symbol
NASDAQ:AMBI
Fax
N/A
Employees
7,000
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$518.81 million
Cash Flow
$0.72 per share
Book Value
$4.90 per share

Miscellaneous

Free Float
26,606,000
Market Cap
$267.17 million
Optionable
Not Optionable
Beta
0.55
2025 Gold Forecast: A Perfect Storm for Demand Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

This page (NASDAQ:AMBI) was last updated on 1/21/2025 by MarketBeat.com Staff
From Our Partners